Table 2 Clinical studies reporting effects of dobutamine on splanchnic haemodynamics
Reference | n | Drug (μg/kg per min) | Splanchnic blood flow | pHi or PCO2 gap | Comments |
|---|---|---|---|---|---|
[24] | 9 | Dobutamine 5 | NA | pHi ↑ | Dobutamine versus transfusions |
[36] | 21 | Dobutamine 5–10 | NA | pHi ↑ | Septic patients with low pHi |
[38] | 15 | Dobutamine 5 + norepinephrine 0.6 | NA | PCO2 gap = | Norepinephrine and epinephrine titrated to obtain MAP ≥ 80 mmHg with stable or increased cardiac index |
|  | 15 | versus epinephrine 0.5 | NA | PCO2 gap ↑ |  |
[39] | 14 | Dobutamine 7.5 + norepinephrine 0.6 mg/hour | ICG clearance = | pHi ↓ | Patients were treated with norepinephrine and dobutamine was added |
[40] | 10 | Dobutamine 7.3 ± 2 | HSBF ≈ | NA | Patients with pancreatitis infused with dobutamine to increase cardiac index by > 25% |
[41] | 36 | Dobutamine 5–10 | HSBF ↑ | PCO2 gap ↓ in patients with fractional splanchnic blood flow < 20% |  |
[42] | 12 | Dobutamine NA + norepinephrine 0.2 ± 0.08 | HSBF ↑ | PCO2 gap = | Septic patients haemodynamically controlled with norepinephrine (MAP > 70 mmHg); dobutamine infused to achieve increase in cardiac index of > 20% |
[43] | 42 | Dobutamine 5–10 | HSBF ↑ | NA | Splanchnic VO2 increased only in patients with increased gradient between hepatic venous and mixed–venous oxygen saturation > 10% |